Arvinas Inc
NASDAQ:ARVN

Watchlist Manager
Arvinas Inc Logo
Arvinas Inc
NASDAQ:ARVN
Watchlist
Price: 13.025 USD 1.05%
Market Cap: $836.5m

Operating Margin

-32.6%
Current
Improving
by 155.5%
vs 3-y average of -188.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-32.6%
=
Operating Income
$-101.9m
/
Revenue
$312.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-32.6%
=
Operating Income
$-101.9m
/
Revenue
$312.3m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Arvinas Inc
NASDAQ:ARVN
912.6m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
533.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
276.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.5B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
146B USD
Loading...
FR
Sanofi SA
PAR:SAN
96.9B EUR
Loading...

Market Distribution

Lower than 80% of companies in the United States of America
Percentile
20th
Based on 14 112 companies
20th percentile
-32.6%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Arvinas Inc
Glance View

Market Cap
836.5m USD
Industry
Pharmaceuticals

In the intricate world of biotechnology, Arvinas Inc. emerges as a pioneer, carving out a niche in the realm of targeted protein degradation. Founded by Dr. Craig Crews, the company stands at the forefront of innovation with its PROTAC® (PROteolysis TArgeting Chimeras) technology. This therapeutic approach cleverly harnesses the cell’s natural protein disposal system to degrade disease-causing proteins that have long evaded traditional drug targeting methods. By linking a target protein to an E3 ubiquitin ligase, PROTAC® molecules mark the unwanted proteins for cellular degradation, a strategy that potentially opens up a multitude of targets previously considered "undruggable." This inventive approach not only holds promise for treating a wide spectrum of diseases, including cancer and neurodegenerative disorders, but also positions Arvinas as a leader in redefining therapeutic paradigms. Focusing its business model on partnerships and collaborations, Arvinas has strategically aligned itself with some of the pharmaceutical industry's heavyweights. Revenue streams are derived from these collaborations, which include potential milestone payments, option fees, and royalties linked to the successful commercialization of therapeutics developed through its proprietary PROTAC® technology. By leveraging strategic alliances, Arvinas not only amplifies its research capabilities but also diversifies financial risk. The company is thus uniquely positioned at the intersection of science and commerce, driving innovation while capitalizing on its cutting-edge platform. This dual focus on robust scientific exploration and strategic financial growth creates a compelling narrative for a biotech company aiming to revolutionize disease treatment.

ARVN Intrinsic Value
5.902 USD
Overvaluation 55%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-32.6%
=
Operating Income
$-101.9m
/
Revenue
$312.3m
What is Arvinas Inc's current Operating Margin?

The current Operating Margin for Arvinas Inc is -32.6%, which is above its 3-year median of -188.2%.

How has Operating Margin changed over time?

Over the last 3 years, Arvinas Inc’s Operating Margin has increased from -201.8% to -32.6%. During this period, it reached a low of -511.5% on Dec 31, 2023 and a high of -22.4% on Mar 31, 2025.

Back to Top